We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.53%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$6.39B
AUM Growth
+$1.46B
Cap. Flow
+$813M
Cap. Flow %
12.72%
Top 10 Hldgs %
30%
Holding
130
New
34
Increased
32
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$114M
2
CNC icon
Centene
CNC
+$75.1M
3
ESPR
Esperion Therapeutics
ESPR
+$67.2M
4
SPOT icon
Spotify
SPOT
+$55.4M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$51.4M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$198M
2
MSFT icon
Microsoft
MSFT
+$102M
3
BAX icon
Baxter International
BAX
+$84.8M
4
MOH icon
Molina Healthcare
MOH
+$65.2M
5
UNH icon
UnitedHealth
UNH
+$50.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.69%
2 Technology 9.35%
3 Communication Services 7.21%
4 Consumer Discretionary 2.57%
5 Financials 2.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$471B
$412M 6.45%
+2,398,900
New +$402M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.3B
$213M 3.34%
1,238,906
+103,379
+9% +$16.9M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$82.4B
$203M 3.18%
+1,239,300
New +$198M
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$192M 3%
5,079,770
-246,901
-5% -$9.44M
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
$184M 2.88%
2,720,218
-112,785
-4% -$6.31M
ELV icon
6
Elevance Health
ELV
$82.9B
$168M 2.64%
707,244
+46,374
+7% +$10.7M
VTRS icon
7
Viatris
VTRS
$20.5B
$162M 2.54%
4,480,720
-143,359
-3% -$5.62M
THC icon
8
Tenet Healthcare
THC
$16.7B
$146M 2.28%
4,336,946
+786,785
+22% +$24.5M
EEM icon
9
PUT
iShares MSCI Emerging Markets ETF
EEM
$28.9B
$130M 2.04%
+3,005,700
New +$139M
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$106M 1.66%
+2,337,225
New +$114M
GOOGL icon
11
Alphabet (Google) Class A
GOOGL
$4.24T
$101M 1.59%
1,795,480
+751,480
+72% +$40.9M
ZBH icon
12
Zimmer Biomet
ZBH
$17.4B
$99.7M 1.56%
921,454
+3,290
+0.4% +$358K
PCRX icon
13
Pacira BioSciences
PCRX
$997M
$99.7M 1.56%
3,110,213
+1,405,605
+82% +$48.5M
CRM icon
14
Salesforce
CRM
$139B
$98.8M 1.55%
724,231
+168,423
+30% +$21.5M
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
$96.4M 1.51%
2,460,157
+1,330,159
+118% +$67.2M
PBYI icon
16
Puma Biotechnology
PBYI
$422M
$94.5M 1.48%
1,596,783
-435,836
-21% -$25.3M
HUM icon
17
Humana
HUM
$47.8B
$92M 1.44%
309,101
-11,349
-4% -$3.32M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$90.3M 1.41%
1,819,315
+869,404
+92% +$42.1M
DVA icon
19
DaVita
DVA
$15B
$89.2M 1.4%
1,285,000
+659,997
+106% +$44.1M
BIDU icon
20
Baidu
BIDU
$36.8B
$89.2M 1.4%
367,146
+138,324
+60% +$34.4M
RVTY icon
21
Revvity
RVTY
$12.3B
$85.1M 1.33%
1,161,817
+80,310
+7% +$6.02M
ABT icon
22
Abbott
ABT
$174B
$81.6M 1.28%
1,337,288
-419,508
-24% -$25.4M
CNC icon
23
Centene
CNC
$32.5B
$80.2M 1.26%
+1,302,436
New +$75.1M
PEN icon
24
Penumbra
PEN
$12.5B
$79.4M 1.24%
574,400
-72,586
-11% -$10.3M
MDCO
25
DELISTED
Medicines Co
MDCO
$76.7M 1.2%
2,088,997
-114,334
-5% -$3.72M
1
2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
AWP
Abacus Wealth Partners Santa Monica, California $1.1B AUM 14.74% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

PFM Health Sciences's Q2 2018 Portfolio in Review

As of Q2 2018, PFM Health Sciences held 130 positions worth $6.39B, up 30% from $4.92B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

PFM Health Sciences deployed $813M of net new capital in Q2 2018, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Clovis Oncology, Inc.: 2,337,225 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 60% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Microsoft, an estimated $102M trimmed.

  • PFM Health Sciences's largest Q2 2018 buy was Clovis Oncology, Inc.: 2,337,225 shares worth $106M.
  • PFM Health Sciences added most to Esperion Therapeutics in Q2 2018, an estimated $67.2M increase.
  • PFM Health Sciences's biggest Q2 2018 reduction was Microsoft, cutting an estimated $102M.
  • PFM Health Sciences fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $198M.
  • PFM Health Sciences's ten largest holdings make up 30% of its $6.39B portfolio in Q2 2018.
  • PFM Health Sciences opened 34 new positions and closed 15 in Q2 2018.
  • PFM Health Sciences's portfolio value rose 30% quarter-over-quarter to $6.39B.

Based on PFM Health Sciences's 13F filing for Q2 2018, filed 14 Aug 2018.